[Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Italy]
BACKGROUND AND OBJECTIVE: Atopic dermatitis (AD) is a chronic, multifactorial, inflammatory condition characterized by a significant impact on patients’ quality of life. Dupilumab is reimbursed by the Italian Medicines Agency (AIFA) for the treatment of adolescent and adult patients with severe AD (...
Main Authors: | Elena Galli, Maria Paola Pedone, Miryana Dobreva, Rossella Bitonti, Roberta Di Turi |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2022-06-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1527 |
Similar Items
-
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01) -
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022-05-01) -
Analisi costo-utilità di dupilumab per il trattamento della dermatite atopica grave negli adulti in Italia
by: Antonio Costanzo, et al.
Published: (2020-08-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01) -
Conjunctivitis as a common adverse effect of dupilumab
in atopic dermatitis
by: Mikołaj Cichoń, et al.
Published: (2023-03-01)